IVERIC bio Inc. (NASDAQ:ISEE)’s traded shares stood at 3.72 million during the last session, with the company’s beta value hitting 1.67. At the close of trading, the stock’s price was $16.36, to imply an increase of 0.49% or $0.08 in intraday trading. The ISEE share’s 52-week high remains $17.03, putting it -4.1% down since that peak but still an impressive 70.23% since price per share fell to its 52-week low of $4.87. The company has a valuation of $1.05B, with an average of 32.16 million shares in intraday trading volume over the past 10 days and average of 5.36 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for IVERIC bio Inc. (ISEE), translating to a mean rating of 1.70. Of 5 analyst(s) looking at the stock, 0 analyst(s) give ISEE a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.27.
IVERIC bio Inc. (NASDAQ:ISEE) trade information
After registering a 0.49% upside in the last session, IVERIC bio Inc. (ISEE) has traded red over the past five days. The stock hit a weekly high of 17.03 this Thursday, 09/16/21, jumping 0.49% in its intraday price action. The 5-day price performance for the stock is 88.26%, and 75.73% over 30 days. With these gigs, the year-to-date price performance is 136.76%. Short interest in IVERIC bio Inc. (NASDAQ:ISEE) saw shorts transact 5.23 million shares and set a 13.76 days time to cover.
Analysts on Wall Street suggest a consensus price target of $21.20, implying an increase of 22.83% to the stock’s current value. The extremes give us $18.00 and $25.00 for target low and target high price respectively. As such, ISEE has been trading -52.81% off suggested target high and -10.02% from its likely low.
IVERIC bio Inc. (ISEE) estimates and forecasts
Looking at statistics comparing IVERIC bio Inc. share performance against respective industry, we note that the company has underperformed competitors. IVERIC bio Inc. (ISEE) shares are 169.08% up over the last 6 months, with its year-to-date growth rate lower than industry average at -3.51% against 7.30%.
IVERIC bio Inc. has its next earnings report out on May 05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. IVERIC bio Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
IVERIC bio Inc. (NASDAQ:ISEE)’s Major holders
IVERIC bio Inc. insiders hold 0.84% of total outstanding shares, with institutional holders owning 93.51% of the shares at 94.30% float percentage. In total, 93.51% institutions holds shares in the company, led by Avoro Capital Advisors LLC. As of Mar 30, 2021, the company held over 7.25 million shares (or 8.04% of shares), all amounting to roughly $44.8 million.
The next major institution holding the largest number of shares is Blackrock Inc. with 7.06 million shares, or about 7.83% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $43.63 million.
We also have Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF as the top two Mutual Funds with the largest holdings of the IVERIC bio Inc. (ISEE) shares. Going by data provided on Dec 30, 2020, Vanguard Total Stock Market Index Fund holds roughly 2.52 million shares. This is just over 2.79% of the total shares, with a market valuation of $17.39 million. Data from the same date shows that the other fund manager holds a little less at 2.33 million, or 2.58% of the shares, all valued at about 14.37 million.